Comparable clinical safety and efficacy of biodegradable versus durable polymer paclitaxel eluting stents despite shorter dual antiplatelet therapy: Insights from a multicenter, propensity score-matched registry

Catheterization and Cardiovascular Interventions

Volumn 82, Issue 3, 2013, Pages

  Buszman, Piotr P ^a   Orlik, Bartlomiej ^a   Trela, Blazej ^a   Milewski, Krzysztof ^a   Kozlowski, Michal ^a   Pruski Jr , MacIej ^a   Drzewiecki, Janusz ^b   Peppas, Athanasios ^c   Granada, Juan F ^c   Kaluza, Greg L ^c   Buszman, Pawel E ^a,b  

^a American Heart of Poland Inc   (Poland)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

^c CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

Author keywords

biodegradable polymer; double anti platelet therapy; durable polymer; paclitaxel eluting stent

Indexed keywords

PACLITAXEL; POLYMER;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BIODEGRADABLE IMPLANT; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DEVICE SAFETY; DIABETES MELLITUS; DISEASE FREE SURVIVAL; DRUG ELUTING STENT; EQUIPMENT DESIGN; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PERCUTANEOUS CORONARY INTERVENTION; STABLE ANGINA PECTORIS; STENT THROMBOSIS; SURVIVAL TIME;

BIODEGRADABLE POLYMER; DOUBLE ANTI-PLATELET THERAPY; DURABLE POLYMER; PACLITAXEL ELUTING STENT;

ABSORBABLE IMPLANTS; ACUTE CORONARY SYNDROME; AGED; ANGINA, STABLE; CARDIOVASCULAR AGENTS; CORONARY STENOSIS; CORONARY THROMBOSIS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; FEMALE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MYOCARDIAL INFARCTION; PACLITAXEL; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; POLAND; POLYMERS; PROPENSITY SCORE; PROSTHESIS DESIGN; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84883237196     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.24732     Document Type: Article

References (21)

1. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994; 331: 489-495.
2. Farb A, Sangiorgi G, Carter AJ, et al. Pathology of acute and chronic coronary stenting in humans. Circulation 1999; 99: 44-52.
3. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007; 356: 998-1008.
4. Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007; 356: 1020-1029.
5. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48: 193-202.
6. Ong AT, McFadden EP, Regar E, et al. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005; 45: 2088-2092.
7. Stone GW, Midei M, Newman W, et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: A randomized trial. JAMA 2008; 299: 1903-1913.
8. Windecker S, Serruys PW, Wandel S, et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): A randomised non-inferiority trial. Lancet 2008; 372: 1163-1173.
9. Mehilli J, Byrne RA, Wieczorek A, et al. Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. Eur Heart J 2008; 29: 1975-1982.
10. Buszman P, Milewski K, Zurakowski A, et al. Novel biodegradable polymer-coated, paclitaxel-eluting stent inhibits neointimal formation in porcine coronary arteries. Kardiol Pol; 68: 503-509.
11. Buszman P, Trznadel S, Milewski K, et al. Novel paclitaxel-eluting, biodegradable polymer coated stent in the treatment of de novo coronary lesions: A prospective multicenter registry. Catheter Cardiovasc Interv 2008; 71: 51-57.
12. Vranckx P, Kint PP, Morel MA, et al. Identifying stent thrombosis, a critical appraisal of the academic research consortium (ARC) consensus definitions: A lighthouse and as a toe in the water. EuroIntervention 2008; 4 (Suppl C): C39-C44.
13. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007; 356: 998-1008.
14. Kedhi E, Joesoef KS, McFadden E, et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): A randomised trial. Lancet 2010; 375: 201-209.
15. Byrne RA, Kastrati A, Kufner S, et al. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: The Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. Eur Heart J 2009; 30: 2441-2449.
16. Kufner S, Massberg S, Dommasch M, et al. Angiographic outcomes with biodegradable polymer and permanent polymer drug-eluting stents. Catheter Cardiovasc Interv 2011; 78: 161-166.
17. Stefanini GG, Byrne RA, Serruys PW, et al. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: A pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. Eur Heart J 2012; 33: 1214-1222.
18. Meredith IT, Verheye S, Dubois CL, et al. Primary endpoint results of the EVOLVE trial: A randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent. J Am Coll Cardiol 2012; 59: 1362-1370.
19. Grube E, Schofer J, Hauptmann KE, et al. A novel paclitaxel-eluting stent with an ultrathin abluminal biodegradable polymer 9-month outcomes with the JACTAX HD stent. JACC Cardiovasc Interv 3: 431-438.
20. Vranckx P, Serruys PW, Gambhir S, et al. Biodegradable-polymer-based, paclitaxel-eluting Infinnium stent: 9-Month clinical and angiographic follow-up results from the SIMPLE II prospective multi-centre registry study. EuroIntervention 2006; 2: 310-317.
21. Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: A randomized controlled trial. JAMA 2005; 294: 1215-1223.